News

Cancer Genetics, Inc. Announces Third Quarter Financial Results

By Jamie on November 13 2013

Test volume increased 71% year-over-year in the third quarter Revenue from commercial sales increased 67% year-over-year in the third quarter RUTHERFORD, NJ (November 13, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, reported financial results for the third quarter ended September […]

Continue Reading

Cancer Genetics, Inc. Announces Conference Call to Discuss Third Quarter Results

By Italia on November 11 2013

RUTHERFORD, N.J. (November 11, 2013) — Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA-based diagnostics company focused on developing genomic-based, oncology tests and services , will hold a conference call on Wednesday, November 13, 2013, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended September 30, 2013. […]

Continue Reading

Cancer Genetics to Showcase Research on its Novel, Patent-Protected, Kidney Cancer Diagnostic Array at the Association for Molecular Pathology 2013 Annual Conference

By Italia on November 9 2013

Additional presentation of multisite institutional study focused on increasing accuracy of next generation sequencing, sponsored and led by Illumina, to feature Cancer Genetics RUTHERFORD, NJ (November 07, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA-based diagnostics company focused on developing genomic-based, oncology tests and services, announced today that it will present […]

Continue Reading

Cancer Genetics, Inc. Granted Patent for Kidney Cancer Diagnosis & Typing Using a Proprietary Genomic Method

By Jamie on November 6 2013

Methods in patent validated by Memorial Sloan-Kettering Cancer Center and The Cleveland Clinic RUTHERFORD, NJ (November 6, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA based diagnostics company focused on developing genomic-based, oncology tests and services, received a formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for […]

Continue Reading

Cancer Genetics Announces Closing of Public Offering of $46 Million of Shares of Common Stock

By Jamie on October 28 2013

RUTHERFORD, NJ (October 28, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the closing of its previously announced public offering of 3,286,700 shares of its common stock (including 428,700 shares that were offered and sold by Cancer Genetics pursuant to the exercise in full of […]

Continue Reading

Cancer Genetics Announces Exercise of Underwriters’ Over-Allotment Option

By Italia on October 25 2013

RUTHERFORD, NJ (October 25, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 428,700 shares of common stock at a price of $14.00 per share, bringing the total gross proceeds […]

Continue Reading

Cancer Genetics Announces Pricing of Public Offering of 2,858,000 Shares of Common Stock

By Jamie on October 22 2013

RUTHERFORD, NJ (October 22, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its underwritten public offering of 2,858,000 shares of its common stock at a price to the public of $14.00 per share.  The gross proceeds to Cancer Genetics from the public […]

Continue Reading

Cancer Genetics, Inc. Will Open Precision Medicine Conference with Keynote Presentation

By Jamie on October 8 2013

“From Vision to Reality, the Cancer Genetics Complete Experience,” will be presented by CGI’s VP of R&D, Dr. Houldsworth RUTHERFORD, NJ (October 8, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, today announced its vice president of R&D, Jane Houldsworth, […]

Continue Reading

Cancer Genetics, Inc. Featured in USA TODAY Article

By Italia on September 20 2013

Special insert in the September 20 print edition of USA TODAY also features panel discussion with Cancer Genetics founder, Dr. Raju Chaganti RUTHERFORD, NJ (September 20, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGIX” or the “Company”), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, was featured in an article […]

Continue Reading

Cancer Genetics, Inc. (CGIX) Expands Relationship with Roche Servicios S.A.

By Jamie on September 18 2013

New initiative to drive test adoption at hospitals and cancer centers throughout Central America and the Caribbean RUTHERFORD, NJ (September 18, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers, expanded its relationship with Roche Servicios S.A., an affiliate of the […]

Continue Reading